These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 32979987)

  • 1. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform.
    Schultze A; Walker AJ; MacKenna B; Morton CE; Bhaskaran K; Brown JP; Rentsch CT; Williamson E; Drysdale H; Croker R; Bacon S; Hulme W; Bates C; Curtis HJ; Mehrkar A; Evans D; Inglesby P; Cockburn J; McDonald HI; Tomlinson L; Mathur R; Wing K; Wong AYS; Forbes H; Parry J; Hester F; Harper S; Evans SJW; Quint J; Smeeth L; Douglas IJ; Goldacre B;
    Lancet Respir Med; 2020 Nov; 8(11):1106-1120. PubMed ID: 32979987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
    Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
    Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
    Suissa S; Dell'Aniello S; Ernst P
    Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma.
    Kew KM; Evans DJ; Allison DE; Boyter AC
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011438. PubMed ID: 26031392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
    Oba Y; Keeney E; Ghatehorde N; Dias S
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
    van Geffen WH; Tan DJ; Walters JA; Walters EH
    Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
    Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
    Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK.
    Bloom CI; Drake TM; Docherty AB; Lipworth BJ; Johnston SL; Nguyen-Van-Tam JS; Carson G; Dunning J; Harrison EM; Baillie JK; Semple MG; Cullinan P; Openshaw PJM;
    Lancet Respir Med; 2021 Jul; 9(7):699-711. PubMed ID: 33676593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study.
    DiSantostefano RL; Sampson T; Le HV; Hinds D; Davis KJ; Bakerly ND
    PLoS One; 2014; 9(5):e97149. PubMed ID: 24878543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
    Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC
    Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.
    Kew KM; Dahri K
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011721. PubMed ID: 26798035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study.
    Aveyard P; Gao M; Lindson N; Hartmann-Boyce J; Watkinson P; Young D; Coupland CAC; Tan PS; Clift AK; Harrison D; Gould DW; Pavord ID; Hippisley-Cox J
    Lancet Respir Med; 2021 Aug; 9(8):909-923. PubMed ID: 33812494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Ann Pharmacother; 2017 Nov; 51(11):945-953. PubMed ID: 28677404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
    Kew KM; Dias S; Cates CJ
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stepwise management of COPD: What is next after bronchodilation?
    Miravitlles M; Matsunaga K; Dreher M
    Ther Adv Respir Dis; 2023; 17():17534666231208630. PubMed ID: 37936381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.